Listing of subscription rights

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN OR SUCH OTHER JURISDICTIONS WHERE THE OFFERING AND SALE OF THE NEW SHARES AND THE SUBSCRIPTION RIGHTS IS RESTRICTED BY LAW.

DiaGenic ASA

Reference is made to the stock exchange announcements made by DiaGenic ASA (“DiaGenic” or the “Company”) on 14 March 2014 regarding the approved prospectus for the rights offering (the “Rights Offering”) and subsequent listing of 100,000,000 new shares (the "New Shares") each with a par value of NOK 0.20 at a subscription price of NOK 0.50 per New Share (the “Prospectus”)

Subscription Period for the Rights Offering:

The subscription period for the Rights Issue commences today, 17 March 2014 and expires at 17:30 hours, Central European Time (“CET”), on 31 March 2014 (the “Subscription Period”). The Subscription Rights will be tradable on Oslo Børs during the Subscription Period under the ticker symbol “DIAG S”. Last day of trading in the subscription rights is 31 March 2014. The subscription rights must be used before expiry of the subscription period, or sold at the latest 31 March 2014.

Subscription rights (the “Subscription Rights”) will be granted to existing shareholders (the "Existing Shareholders") of DiaGenic as of the end of 25 February 2014 as appearing in the Norwegian Central Securities Depository ("VPS") on 28 February 2014 (the “Record Date”). The Rights Offering is fully underwritten by an underwriting syndicate.

Each Eligible Shareholder will be granted 12.25509 Subscription Rights for each Share registered as held by such Eligible Shareholder as of the Record Date rounded down to the nearest whole Subscription Right. Each Subscription Right will, subject to applicable securities laws, give the right to subscribe for and be allocated one New Share. Oversubscription and subscription without Subscription Rights is permitted.

Important notice: Subscription Rights that are not used to subscribe for New Shares before the end of the Subscription Period will have no value and will lapse without compensation to the holder. Shareholders not using their subscription rights will have their shareholding significantly diluted.

The Subscription rights are tradable and are, based on recent trading, expected to have a financial value as DiaGenic’s shares are currently traded at a higher price than the subscription price.

Manager for the Rights Issue is Arctic Securities ASA

The information in this notice is not complete. For further information see Prospectus dated 14 March 2014 which is available online at www.diagenic.com and www.arcticsec.no. The Prospectus can also be obtained physically from the Manager and will be available to the public from 17 March 2014:

The Manager:

Arctic Securities ASA

P.O. Box 1833 Vika

Haakon VII's gt. 5

0123 Oslo

Norway

www.arcticsec.no